TICKERNERD
Menu
CVSAConsumer Defensive · Education & Training Services

CVSA Stock Forecast: Covista, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$124
−3.39% on the day

The 4 Wall Street analysts covering Covista, Inc. hold a median 12-month price target of $161 — +29.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 77 of 100 as at 31 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$4.2B
Ticker Nerd rank
77/ 100
Median analyst target
$161
Analysts covering
4
Revenue$501.4M+9.7% y/y
Operating income$96.5M
Net income$71.7M
Free cash flow$97.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−5.6%
1M
+1.8%
YTD
+20.2%
1Y
−12.3%
From 52W high
−12.3%
From 52W low
+39.2%
$89
$142
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CVSA stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Covista, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
77/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Issuance
95
Quality
82
Revisions
71
Accruals
67
Value
64
Momentum
57
Growth
45
Volatility
38
Size
25

Issuance (95): The share count has been shrinking and the company is not leaning on new borrowing.

Volatility (38): The share price moves around a lot.

Size (25): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CVSA stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CVSA, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$80$100$120$140$160$180Jan 26Apr 26Jul 26Oct 26CVSAHigh $175Median $161Low $140

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
3 Buy1 Hold0 Sell
Low $140Median $161High $175

The green dot is the last close — the median target sits +29.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
5 Oct 2026BMO CapitalMaintainsOutperform$148 → $145
3 Sept 2026Truist SecuritiesDowngradeHold—
3 Sept 2026Truist SecuritiesDowngradeHold$140
8 June 2026Barrington ResearchMaintainsOutperform—
8 June 2026Barrington ResearchMaintainsOutperform$170
11 May 2026Truist SecuritiesMaintainsBuy—
17 Apr 2026Barrington ResearchMaintainsOutperform—
24 Mar 2026Truist SecuritiesInitiatesBuy—
2 Mar 2026Barrington ResearchMaintainsOutperform—
29 Jan 2026Barrington ResearchMaintainsOutperform—
31 Oct 2025Barrington ResearchMaintainsOutperform—
15 Oct 2025Barrington ResearchMaintainsOutperform—
23 Sept 2025Barrington ResearchMaintainsOutperform—
8 Aug 2025Barrington ResearchMaintainsOutperform$140 → $150
30 July 2025Barrington ResearchMaintainsOutperform$140
12 May 2025BMO CapitalMaintainsOutperform$115 → $132
9 May 2025Barrington ResearchMaintainsOutperform$120 → $140
23 Apr 2025JefferiesInitiatesBuy$135
15 Apr 2025Barrington ResearchMaintainsOutperform$120
3 Feb 2025BMO CapitalMaintainsOutperform$108 → $115

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CVSA appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CVSA vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Covista, Inc. returned −12.3% against +12.4% for the S&P 500, dividends included.

CVSA vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26CVSAS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CVSA analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
+1.8%
Analysts raising
2
Analysts cutting
1
Fundamentals

Covista, Inc. (CVSA) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.7×

Cheaper than 43% of US stocks

Price / sales
2.1×

Cheaper than 49% of US stocks

Price / book
2.9×

Cheaper than 31% of US stocks

EV / EBITDA
10.2×

Cheaper than 34% of US stocks

Growth & margins
Revenue growth (YoY)
10.7%

Higher than 52% of US stocks

Earnings growth (YoY)
9.0%

Higher than 67% of US stocks

Gross margin
56.8%

Higher than 70% of US stocks

Operating margin
19.2%

Higher than 78% of US stocks

Net margin
12.8%

Higher than 75% of US stocks

Returns & dividend
Return on equity
19.3%

Higher than 79% of US stocks

Return on assets
8.7%

Higher than 89% of US stocks

Dividend yield
0.3%

Higher than 64% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Covista, Inc. (CVSA) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Covista, Inc. has a market value of $4.2B and an enterprise value of $4.7B.

  • Revenue in the twelve months to 30 June 2026: $2.0B. The latest quarter grew 10.7% year on year.

  • Net income over the same four quarters: $251.6M, a 12.9% net margin.

  • Diluted earnings per share, trailing twelve months: $7.04.

  • Free cash flow in the twelve months to 30 June 2026: $392.7M, after $77.7M of capital spending.

  • Covista, Inc. spent $239.9M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 34.0M.

  • Trailing P/E: 15.7×; forward P/E: 12.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.29%, paying out 0% of earnings.

  • Covista, Inc. employs 4,736 people — $413K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

CVSA vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelEducation & Training Services
CompanyMarket capTKN rank
CVSACovista, Inc.$4.2B77
LAURLaureate Education, Inc.$4.7B69
LOPEGrand Canyon Education, Inc.$3.9B78
XXITwenty One Capital, Inc.$3.6B3
LRNStride, Inc.$3.3B66
MHMcGraw Hill, Inc.$2.6B73
PRDOPerdoceo Education Corp.$1.9B92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Covista, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CVSA news & analysis

Covista: Stronger Results Keep Me Bullish, But Cash Flow Needs To Improve

Seeking Alpha · 30 Oct 2026neutral

Covista’s recent results reinforced confidence in its business direction and profitability improvements, led by Walden’s 14.1% revenue growth and 16.1% EBITDA growth. Chamberlain’s profitability remained flat amid expansion investments, while declining operating cash flow and rising credit-loss provisions raised concerns about growth quality.

Why it matters — CVSA watchers may weigh Walden’s gains against flat Chamberlain profitability and cash-flow concerns when assessing the quality of the company’s results.

Covista (CVSA) Beats Q1 Earnings and Revenue Estimates

Zacks Investment Research · 30 Oct 2026positive

Covista reported quarterly earnings of $2.19 per share, above the Zacks Consensus Estimate of $1.90. Earnings were $1.75 per share a year earlier.

Why it matters — CVSA watchers may note the reported earnings exceeded the consensus estimate and were higher than a year ago.

Covista Inc. (CVSA) Q1 2027 Earnings Call Transcript

Seeking Alpha · 29 Oct 2026neutral

Seeking Alpha published a transcript of Covista Inc.’s Q1 2027 earnings call.

Why it matters — The transcript provides CVSA watchers with a source to review the company’s discussion of its first-quarter results.

Covista Reports First Quarter Fiscal Year 2027 Results; Raises Fiscal Year 2027 Revenue and Adjusted EPS Guidance

Business Wire · 29 Oct 2026positive

Covista reported first-quarter fiscal 2027 results and said it launched Purpose at Scale, a three-year strategy focused on training healthcare professionals through operational excellence, platform extension, employer integration, and technology. The headline says the company raised its fiscal 2027 revenue and adjusted EPS guidance.

Why it matters — CVSA watchers may note the updated full-year guidance and the launch of the company’s three-year strategy.

Covista Recognized by TIME and Newsweek for Growth, Workplace Culture and Sustainability

Business Wire · 27 Oct 2026positive

Covista, formerly Adtalem Global Education, said it was recognized in four rankings from TIME and Newsweek. The honors assess growth, financial stability, workplace culture and sustainability performance.

Why it matters — The recognition offers CVSA watchers information about how the company is being evaluated across business growth, workplace and sustainability measures.

FAQ

Frequently asked questions about CVSA stock

What is the CVSA stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Covista, Inc. have a median 12-month price target of $161, with estimates ranging from $140 to $175. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CVSA stock a buy right now?

Of the 4 analysts covering Covista, Inc., 3 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Covista, Inc. 77 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CVSA?

As at 31 Oct 2026, Covista, Inc. ranks 77 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Issuance (95 of 100).

Will CVSA stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +29.0% from the last close, and Ticker Nerd's factor model ranks Covista, Inc. 77 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CVSA stock forecast for 2030?

No analyst covering Covista, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CVSA are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $140 to $175 over the next 12 months.

How has CVSA stock performed over the past year?

Covista, Inc. returned -12.3% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Covista, Inc. do?

Covista Inc. is a healthcare education company that provides post-secondary training through a portfolio of accredited institutions in the United States and select Caribbean markets.

What is the latest news on CVSA?

The most recent item we track (Seeking Alpha, 30 Oct 2026): "Covista: Stronger Results Keep Me Bullish, But Cash Flow Needs To Improve". Covista’s recent results reinforced confidence in its business direction and profitability improvements, led by Walden’s 14.1% revenue growth and 16.1% EBITDA growth. Chamberlain’s profitability remained flat amid expansion investments, while declining operating cash flow and rising credit-loss provisions raised concerns about growth quality.

Company

About Covista, Inc.

Covista Inc. is a healthcare education company that provides post-secondary training through a portfolio of accredited institutions in the United States and select Caribbean markets. Its current operations center on preparing students for careers in nursing, medicine, veterinary medicine, and other health-related professions through degree programs, online learning, and campus-based instruction. Covista’s business is organized around Chamberlain, Walden, and Medical and Veterinary segments, each serving different areas of professional education and workforce development. The company supports a broad student population with programs designed for flexible access, academic progression, and clinical preparation, making it an important provider in the healthcare education market. Based in Chicago, Illinois, Covista focuses on serving learners seeking specialized credentials for roles across the healthcare system.

CEO Mr. Stephen W. Beard J.D. · 4,736 employees · United States · https://www.covista.com